LRRK2 and Parkinson disease: Statins have been shown to reduce intraneuronal α-synuclein aggregations in animal PD models and restore neurite degeneration by augmenting the Akt/NRF2 pathway and inhibiting downstream GSK3β activity in transgenic LRRK2-G2019S Drosophila and knock-in mouse models [14].